EMEA (Europe, Middle East and Africa) Narcolepsy Therapeutics Market Report 2018

Table of Contents

EMEA (Europe, Middle East and Africa) Narcolepsy Therapeutics Market Report 2018

1 Narcolepsy Therapeutics Overview

• 1.1 Product Overview and Scope of Narcolepsy Therapeutics
• 1.2 Classification of Narcolepsy Therapeutics
  • 1.2.1 EMEA Narcolepsy Therapeutics Market Size (Sales) Comparison by Type (2013-2025)
  • 1.2.2 EMEA Narcolepsy Therapeutics Market Size (Sales) Market Share by Type (Product Category) in 2017
  • 1.2.3 Central nervous system stimulants
  • 1.2.4 Sodium Oxybate
  • 1.2.5 Selective Serotonin Reuptake Inhibitor (SSRI)
  • 1.2.6 Tricyclic Antidepressants
  • 1.2.7 Others
• 1.3 EMEA Narcolepsy Therapeutics Market by Application/End Users
  • 1.3.1 EMEA Narcolepsy Therapeutics Sales (Volume) and Market Share Comparison by Application (2013-2025)
  • 1.3.2 Narcolepsy With Cataplexy
  • 1.3.3 Narcolepsy Without Cataplexy
  • 1.3.4 Secondary Narcolepsy
• 1.4 EMEA Narcolepsy Therapeutics Market by Region
  • 1.4.1 EMEA Narcolepsy Therapeutics Market Size (Value) Comparison by Region (2013-2025)
  • 1.4.2 Europe Status and Prospect (2013-2025)
  • 1.4.3 Middle East Status and Prospect (2013-2025)
  • 1.4.4 Africa Status and Prospect (2013-2025)
• 1.5 EMEA Market Size (Value and Volume) of Narcolepsy Therapeutics (2013-2025)
  • 1.5.1 EMEA Narcolepsy Therapeutics Sales and Growth Rate (2013-2025)
  • 1.5.2 EMEA Narcolepsy Therapeutics Revenue and Growth Rate (2013-2025)

2 EMEA Narcolepsy Therapeutics Competition by Manufacturers/Players/Suppliers, Region, Type and Application

• 2.1 EMEA Narcolepsy Therapeutics Market Competition by Players/Manufacturers
  • 2.1.1 EMEA Narcolepsy Therapeutics Sales Volume and Market Share of Major Players (2013-2018)
  • 2.1.2 EMEA Narcolepsy Therapeutics Revenue and Share by Players (2013-2018)
  • 2.1.3 EMEA Narcolepsy Therapeutics Sale Price by Players (2013-2018)
• 2.2 EMEA Narcolepsy Therapeutics (Volume and Value) by Type/Product Category
  • 2.2.1 EMEA Narcolepsy Therapeutics Sales and Market Share by Type (2013-2018)
  • 2.2.2 EMEA Narcolepsy Therapeutics Revenue and Market Share by Type (2013-2018)
  • 2.2.3 EMEA Narcolepsy Therapeutics Sale Price by Type (2013-2018)
• 2.3 EMEA Narcolepsy Therapeutics (Volume) by Application
• 2.4 EMEA Narcolepsy Therapeutics (Volume and Value) by Region
  • 2.4.1 EMEA Narcolepsy Therapeutics Sales and Market Share by Region (2013-2018)
  • 2.4.2 EMEA Narcolepsy Therapeutics Revenue and Market Share by Region (2013-2018)
  • 2.4.3 EMEA Narcolepsy Therapeutics Sales Price by Region (2013-2018)

3 Europe Narcolepsy Therapeutics (Volume, Value and Sales Price), by Players, Countries, Type and Application

• 3.1 Europe Narcolepsy Therapeutics Sales and Value (2013-2018)
  • 3.1.1 Europe Narcolepsy Therapeutics Sales Volume and Growth Rate (2013-2018)
  • 3.1.2 Europe Narcolepsy Therapeutics Revenue and Growth Rate (2013-2018)
• 3.2 Europe Narcolepsy Therapeutics Sales and Market Share by Type
• 3.3 Europe Narcolepsy Therapeutics Sales and Market Share by Application
• 3.4 Europe Narcolepsy Therapeutics Sales Volume and Value (Revenue) by Countries
  • 3.4.1 Europe Narcolepsy Therapeutics Sales Volume by Countries (2013-2018)
  • 3.4.2 Europe Narcolepsy Therapeutics Revenue by Countries (2013-2018)
  • 3.4.3 Germany Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 3.4.4 France Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 3.4.5 UK Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 3.4.6 Russia Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 3.4.7 Italy Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 3.4.8 Benelux Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)

4 Middle East Narcolepsy Therapeutics (Volume, Value and Sales Price), by Region, Type and Application

• 4.1 Middle East Narcolepsy Therapeutics Sales and Value (2013-2018)
  • 4.1.1 Middle East Narcolepsy Therapeutics Sales Volume and Growth Rate (2013-2018)
  • 4.1.2 Middle East Narcolepsy Therapeutics Revenue and Growth Rate (2013-2018)
• 4.2 Middle East Narcolepsy Therapeutics Sales and Market Share by Type
• 4.3 Middle East Narcolepsy Therapeutics Sales and Market Share by Application
• 4.4 Middle East Narcolepsy Therapeutics Sales Volume and Value (Revenue) by Countries
  • 4.4.1 Middle East Narcolepsy Therapeutics Sales Volume by Countries (2013-2018)
  • 4.4.2 Middle East Narcolepsy Therapeutics Revenue by Countries (2013-2018)
  • 4.4.3 Saudi Arabia Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 4.4.4 Israel Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 4.4.5 UAE Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 4.4.6 Iran Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)

5 Africa Narcolepsy Therapeutics (Volume, Value and Sales Price) by Players, Countries, Type and Application

• 5.1 Africa Narcolepsy Therapeutics Sales and Value (2013-2018)
  • 5.1.1 Africa Narcolepsy Therapeutics Sales Volume and Growth Rate (2013-2018)
  • 5.1.2 Africa Narcolepsy Therapeutics Revenue and Growth Rate (2013-2018)
• 5.2 Africa Narcolepsy Therapeutics Sales and Market Share by Type
• 5.3 Africa Narcolepsy Therapeutics Sales and Market Share by Application
• 5.4 Africa Narcolepsy Therapeutics Sales Volume and Value (Revenue) by Countries
  • 5.4.1 Africa Narcolepsy Therapeutics Sales Volume by Countries (2013-2018)
  • 5.4.2 Africa Narcolepsy Therapeutics Revenue by Countries (2013-2018)
  • 5.4.3 South Africa Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 5.4.4 Nigeria Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 5.4.5 Egypt Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)
  • 5.4.6 Algeria Narcolepsy Therapeutics Sales and Growth Rate (2013-2018)

6 EMEA Narcolepsy Therapeutics Manufacturers/Players Profiles and Sales Data

• 6.1 Addrenex Pharmaceuticals, Inc.
  • 6.1.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.1.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.1.2.1 Product A
    • 6.1.2.2 Product B
  • 6.1.3 Addrenex Pharmaceuticals, Inc. Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.1.4 Main Business/Business Overview
• 6.2 Teva Pharmaceutical Industries Ltd.
  • 6.2.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.2.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.2.2.1 Product A
    • 6.2.2.2 Product B
  • 6.2.3 Teva Pharmaceutical Industries Ltd. Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.2.4 Main Business/Business Overview
• 6.3 Jazz Pharmaceuticals PLC
  • 6.3.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.3.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.3.2.1 Product A
    • 6.3.2.2 Product B
  • 6.3.3 Jazz Pharmaceuticals PLC Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.3.4 Main Business/Business Overview
• 6.4 Graymark Healthcare, Inc.
  • 6.4.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.4.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.4.2.1 Product A
    • 6.4.2.2 Product B
  • 6.4.3 Graymark Healthcare, Inc. Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.4.4 Main Business/Business Overview
• 6.5 Arena Pharmaceuticals, Inc.
  • 6.5.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.5.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.5.2.1 Product A
    • 6.5.2.2 Product B
  • 6.5.3 Arena Pharmaceuticals, Inc. Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.5.4 Main Business/Business Overview
• 6.6 BIOPROJET
  • 6.6.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.6.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.6.2.1 Product A
    • 6.6.2.2 Product B
  • 6.6.3 BIOPROJET Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.6.4 Main Business/Business Overview
• 6.7 Shire
  • 6.7.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.7.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.7.2.1 Product A
    • 6.7.2.2 Product B
  • 6.7.3 Shire Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.7.4 Main Business/Business Overview
• 6.8 Ligand Pharmaceuticals, Inc.
  • 6.8.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.8.2 Narcolepsy Therapeutics Product Type, Application and Specification
    • 6.8.2.1 Product A
    • 6.8.2.2 Product B
  • 6.8.3 Ligand Pharmaceuticals, Inc. Narcolepsy Therapeutics Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.8.4 Main Business/Business Overview

7 Narcolepsy Therapeutics Manufacturing Cost Analysis

• 7.1 Narcolepsy Therapeutics Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Price Trend of Key Raw Materials
  • 7.1.3 Key Suppliers of Raw Materials
  • 7.1.4 Market Concentration Rate of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
  • 7.2.1 Raw Materials
  • 7.2.2 Labor Cost
  • 7.2.3 Manufacturing Expenses
• 7.3 Manufacturing Process Analysis of Narcolepsy Therapeutics

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

• 8.1 Narcolepsy Therapeutics Industrial Chain Analysis
• 8.2 Upstream Raw Materials Sourcing
• 8.3 Raw Materials Sources of Narcolepsy Therapeutics Major Manufacturers in 2017
• 8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
  • 9.1.3 Marketing Channel Development Trend
• 9.2 Market Positioning
  • 9.2.1 Pricing Strategy
  • 9.2.2 Brand Strategy
  • 9.2.3 Target Client
• 9.3 Distributors/Traders List

10 Market Effect Factors Analysis

• 10.1 Technology Progress/Risk
  • 10.1.1 Substitutes Threat
  • 10.1.2 Technology Progress in Related Industry
• 10.2 Consumer Needs/Customer Preference Change
• 10.3 Economic/Political Environmental Change

11 EMEA Narcolepsy Therapeutics Market Forecast (2018-2025)

• 11.1 EMEA Narcolepsy Therapeutics Sales, Revenue and Price Forecast (2018-2025)
  • 11.1.1 EMEA Narcolepsy Therapeutics Sales and Growth Rate Forecast (2018-2025)
  • 11.1.2 EMEA Narcolepsy Therapeutics Revenue and Growth Rate Forecast (2018-2025)
  • 11.1.3 EMEA Narcolepsy Therapeutics Price and Trend Forecast (2018-2025)
• 11.2 EMEA Narcolepsy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
• 11.3 Europe Narcolepsy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
• 11.4 Middle Eastt Narcolepsy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
• 11.5 Africa Narcolepsy Therapeutics Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
• 11.6 EMEA Narcolepsy Therapeutics Sales Forecast by Type (2018-2025)
• 11.7 EMEA Narcolepsy Therapeutics Sales Forecast by Application (2018-2025)

12 Research Findings and Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources